DUBLIN, Feb. 25, 2020 /PRNewswire/ -- The "Fiducial Markers Market by Product (Metal Based Markers (Gold, Gold Combination) Polymer Markers), Cancer Type (Prostate, Lung, Breast), Modality (CT, CBCT, MRI, Ultrasound), End-user (Hospitals, Outpatient Facilities) - Global Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.
The global fiducial markers market is valued at USD 95 million in 2019 and expected to reach USD 123 million by 2025, at a CAGR of 4.5% from 2019 to 2025. In 2018, the market was dominated by CIVCO Radiotherapy (US), IZI Medical Products (US), Boston Scientific Corporation (US), Naslund Medical AB (Sweden), and IBA (Belgium).
The growth of the fiducial markers market is mainly attributed to factors such as the growing incidences of cancer, growing adoption of radiotherapy procedures, improving reimbursement scenario, and rising awareness on radiotherapy. These factors have prompted market players to improve and strengthen their current manufacturing and distribution capabilities - especially in emerging markets, which are expected to witness the highest growth. However, a dearth of skilled professionals, high marker costs, and a lack of adequate healthcare infrastructure are expected to limit market growth during the forecast period.
The metal-based markers segment commanded the largest share of the fiducial markers market in 2018.
Based on the product, the fiducial markers market is segmented into metal-based, polymer-based, and other fiducial markers. The metal-based markers segment is further subsegmented into pure gold markers, gold combination markers, and other metal-based markers (tungsten, platinum, and nitinol, among others). The metal-based markers segment commanded the largest share of the fiducial markers market in 2018. The growing adoption of IGRT for the treatment of prostate cancer and the rising incidences of prostate cancer are expected to fuel the adoption of metal-based fiducial markers in the near future.
The CT/CBCT segment held the major share of the global market in 2018.
In terms of modality, the fiducial markers market is classified into CT/CBCT, MRI, ultrasound, and radiotherapy. The CT/CBCT segment held the major share of the global market in 2018. It is anticipated to reach USD 54 million by 2025. CBCT is preferred for prostate and lung cancer indications, as it can effectively detect changes in the position of cancer tumors. This is supporting the growth of the CT/CBCT segment.
North America is projected to hold the largest share of the market.
The fiducial markers market, by region, is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. North America is projected to hold the largest share of the market, by region, during the forecast period. This is attributed to the expansion of the target patient population, favorable reimbursement scenario, greater accessibility to radiotherapy procedures, and the presence of major players in this region.
Key Topics Covered
1 Introduction
2 Research Methodology
3 Executive Summary
4 Premium Insights
4.1 Fiducial Markers: Market Overview
4.2 Fiducial Markers Market, By Product & Region, 2019
4.3 Market, By Modality, 2019-2025
4.4 Market, By Cancer Type, 2019 vs. 2025
4.5 Market Share, By End-user, 2019 vs. 2025
4.6 Geographic Snapshot of the Market, 2019
5 Market Overview
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Growing Incidence of Cancer
5.2.1.2 Improving Reimbursement Scenario
5.2.1.3 Rising Awareness on Radiotherapy
5.2.1.4 Rising Investments and Funding for Cancer Research
5.2.2 Restraints
5.2.2.1 Lack of Adequate Healthcare Infrastructure and Premium Pricing of Modalities
5.2.2.2 Alternative Therapies and High Marker Costs
5.2.3 Opportunities
5.2.3.1 Emerging Economies
5.2.4 Challenges
5.2.4.1 Complications Associated With the Placement of Fiducial Markers
5.2.4.2 Shortage of Trained Personnel
6 Market, By Product
6.1 Introduction
6.2 Metal-Based Markers
6.2.1 Pure Gold Markers
6.2.1.1 Pure Gold Markers Hold the Largest Share of the Metal-Based Market
6.2.2 Gold Combination Markers
6.2.2.1 High-Precision Advantages and Versatility are Driving Demand for Gold Combination Markers
6.2.3 Other Metal-Based Markers
6.3 Polymer-Based Markers
6.3.1 Visibility Limitations Have Affected Demand for Polymer-Based Markers
6.4 Other Fiducial Markers
7 Market, By Modality
7.1 Introduction
7.2 CT/CBCT
7.2.1 Technological Advancements and Rising Adoption of CBCT are Expected to Fuel Market Growth
7.3 Ultrasound
7.3.1 Rising Preference for Minimally Invasive Procedures is Driving Demand for Ultrasound
7.4 MRI
7.4.1 High Adoption of Combined CT-MRI Modalities for FM Localization Will Drive Segmental Growth
7.5 Radiotherapy
7.5.1 High Success Rate of SBRT Using Radiotherapy Systems Will Drive the Segment Growth
8 Market, By Cancer Type
8.1 Introduction
8.2 Prostate Cancer
8.2.1 Prostate Cancer Holds the Largest Share of the Market, By Cancer Type
8.3 Lung Cancer
8.3.1 Technological Advancements and Product Approvals Will Drive Market Growth
8.4 Gastric Cancer
8.4.1 High Incidence of Gastric Cancer and Advancements in Treatment Support Market Growth
8.5 Breast Cancer
8.5.1 Efficacy of Advanced Radiology Treatment for Breast Cancer Will Ensure the Growth of the Market
8.6 Other Cancers
9 Market, By End User
9.1 Introduction
9.2 Hospitals & Outpatient Facilities
9.2.1 Hospitals & Outpatient Facilities Hold the Largest Share of the Market
9.3 Independent Radiotherapy Centers
9.3.1 Unfavorable Reimbursement Scenario Will Hamper Growth
9.4 Cancer Research Centers
9.4.1 Rising Investments and Funding Will Increase Research Activities and Support Market Growth
10 Market, By Region
10.1 Introduction
10.2 North America
10.2.1 US
10.2.1.1 US Commanded the Largest Share of the Market in 2018
10.2.2 Canada
10.2.2.1 Public-Private Initiatives are Expected to Support the Adoption of Radiotherapy Procedures and Fiducial Markers
10.3 Europe
10.3.1 Germany
10.3.1.1 Favorable Reimbursement Scenario for Radiotherapy is Supporting Market Growth in Germany
10.3.2 UK
10.3.2.1 Rising Cancer Incidence and the Presence of Highly Developed Healthcare Infrastructure are Supporting Market Growth in the UK
10.3.3 France
10.3.3.1 Increasing Access to Radiotherapy Will Drive Market Growth
10.3.4 Spain
10.3.4.1 Shortage of Human Resources and Lack of Accessibility May Hinder Market Growth
10.3.5 Italy
10.3.5.1 Rising Research Activities Will Support Market Growth
10.3.6 Rest of Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.1.1 Japan Dominates the APAC Market
10.4.2 China
10.4.2.1 China Will Register the Highest Growth in the APAC Market Due to the Growing Target Patient Population
10.4.3 India
10.4.3.1 Indian Market is Expected to be Driven By the Surge in Patient Population and Favorable Government Initiatives
10.4.4 South Korea
10.4.4.1 Growing Adoption of Advanced EBRT is Contributing to Market Growth in the Country
10.4.5 Australia
10.4.5.1 Favorable Reimbursement Scenario Will Support Market Growth
10.4.6 Rest of APAC
10.5 Latin America
10.5.1 Brazil
10.5.1.1 Brazil Held the Largest Share of the Latin American Market in 2018
10.5.2 Mexico
10.5.2.1 Initiatives are Being Undertaken to Spread Awareness and Boost Access to Radiotherapy
10.5.3 Rest of LATAM
10.6 Middle East & Africa
10.6.1 Poor Healthcare Infrastructure and Reimbursement Scenario Restrain Market Growth
11 Competitive Landscape
11.1 Overview
11.2 Market Share Analysis
11.3 Competitive Scenario
11.3.1 Key Product Launches and Enhancements
11.3.2 Key Agreements, Partnerships, and Collaborations
11.3.3 Key Acquisitions
11.3.4 Key Expansions
11.4 Competitive Leadership Mapping
11.4.1 Visionary Leaders
11.4.2 Innovators
11.4.3 Dynamic Differentiators
11.4.4 Emerging Companies
12 Company Profiles
12.1 CIVCO Radiotherapy
12.2 Boston Scientific Corporation
12.3 IZI Medical Products
12.4 IBA
12.5 Naslund Medical AB
12.6 Medtronic
12.7 Best Medical International Inc.
12.8 Nanovi A/S
12.9 Carbon Medical Technologies
12.10 Eckert & Ziegler
12.11 Innovative Oncology Solutions
12.12 QlRad Inc.
12.13 Stellar Medical
12.14 JJ-Medtech
12.15 QFIX
12.16 Other Companies
12.16.1 Varian Medical Systems Inc.
12.16.2 Beekley Corporation
12.16.3 Innomedicus AG
12.16.4 Meditronix Corporation
12.16.5 Seedos Ltd.
For more information about this report visit https://www.researchandmarkets.com/r/buzu3m
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
